Systems for producing cellular immunotherapeutics and methods of use thereof
AssigneeNortheastern University
InventorShashi K. Murthy
Life of this patent
Estimating the term…
Abstract
Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease.
Claims17
A system for producing an immunotherapeutic product, the system comprising:
- a first module configured for processing cellular material associated with a disease of a patient, the first module comprising a fluid inlet port and a separate fluid outlet port;
- a second module configured for generating immune cells, the second module comprising a cell culture chamber, a fluid inlet port, and a separate fluid outlet port disposed on opposite sides of the cell culture chamber, the separate fluid outlet port positioned at a height above the fluid inlet port, wherein the cell culture chamber comprises a monocyte-binding substrate, and wherein the fluid inlet port and the separate fluid outlet port are fluidically coupled to the cell culture chamber and configured to provide flow of a liquid culture medium across the monocyte-binding substrate from the fluid inlet port to the separate fluid outlet port that minimizes mechanical detachment of cells from the monocyte-binding substrate;
- and
- a third module separately coupled to and in fluidic communication with each of the first and second modules, the third module comprising a first inlet port for fluidic communication with the first module and a separate second inlet port for fluidic communication with the second module such that the third module separately receives a flow of processed cellular material from the first module and separately receives a flow of immune cells from the second module, wherein the third module is configured to co-culture the processed cellular material and the immune cells to produce an immunotherapeutic product.
Dependencies are inferred from the claim text.